OSAKA, Japan & CAMBRIDGE, Mass.– Takeda (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, Portugal between April 23 and 26, 2022. The exploratory data presented at both meetings provide an opportunity to share important new analyses of LIVTENCITY™ (maribavir) with the transplant and infectious disease communities. These data announcements follow completion of patient enrollment in Takeda’s AURORA (TAK-620-302) study, focusing on LIVTENCITY for first-line use in hematopoietic stem cell transplant (HSCT) recipients with cytomegalovirus (CMV) infection/disease.
The abstracts include additional analyses that underscore the relevance of the multicenter, randomized, open-label Phase 3 SOLSTICE trial data, which supported the U.S. Food and Drug Administration (FDA) approval of LIVTENCITY as the first and only treatment for people ages 12 and older and weighing at least 35kg with post-transplant CMV infection/disease, refractory† (with or without genotypic resistance‡) to conventional antiviral therapies (one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir).5,6
CMV is one of the most common and serious post-transplant infections with an estimated global incidence rate of around 16-56% in solid organ transplant (SOT) recipients and 30-70% in HSCT recipients,7–12 and can lead to serious consequences, including loss of the transplanted organ and failure of the graft.13,14
“When managing post-transplant CMV infections, we’re always looking for additional treatment options for patients that are refractory with or without resistance,” said Barbara Alexander, MD, Professor of Medicine and Professor of Pathology at Duke University School of Medicine. “The additional LIVTENCITY data being presented at the Tandem Meetings and ECCMID, including time to confirmed CMV DNA level <LLOQ, patient safety data, and potential impact to hospitalization and length of stay is encouraging towards outcomes for transplant patients.”
